Project Grant R03CA308467
Award Date 4/1/26
Completion Date 3/31/28
Dollars Obligated $156K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of Colorado-Denver a Project Grant totaling $491,315 under the Cancer Biology Research program (CFDA 93.396) on September 12, 2025, with a completion date of August 31, 2029. This award supports the Functional Genomics Shared Resource (FGSR) at the University of Colorado Cancer Center, led by Principal Investigator Dr. Molishree Joshi. The FGSR provides critical research support services across three major...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $584,510 to the University of Colorado-Denver on September 12, 2025, under the Cancer Biology Research program (CFDA 93.396) to support the development and implementation of advanced spatial transcriptomics and proteomics technologies for studying tumor microenvironments. Through the Human Immune Monitoring Shared Resource (HIMSR) at the University of Colorado Cancer Center, this funding supports a...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Miami's Office of Research Administration within the School of Medicine a Project Grant totaling $109,076.00 under the Cancer Research Manpower program (CFDA 93.398) on December 17, 2025. The award supports biomedical research training and career development initiatives focused on cancer research through September 1, 2029. This project grant funds the institution's capacity to provide integrated...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute awarded $197,518 to The Children's Hospital of Philadelphia Research Institute under the Cancer Treatment Research program (CFDA 93.395) on September 8, 2025, with a completion date of August 31, 2030. This Project Grant supports the development of rare tumor clinical research capabilities and services to address the significant gap in clinical trial availability and patient care coordination for rare cancers. The awardee will expand...
- Federal Project Grant Summary The National Cancer Institute (NCI) awarded $770,666 to the University of Colorado (The Regents of the University of Colorado) under the Cancer Biology Research program (CFDA 93.396) on March 19, 2026, with completion targeted for February 28, 2028. The project, "Splicing-Mediated Dysregulation of Interferon Signaling in Cancer," will investigate how transposon-derived exonized variants of the IFNAR2 gene contribute to cancer treatment resistance. The...
- Federal Grant Award Summary The National Cancer Institute awarded a $122,610 Project Grant to the University of Pennsylvania on August 11, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award, with a completion date of July 31, 2030, supports the development of a system to advance National Cancer Institute (NCI)-sponsored clinical trials for patients with rare gastrointestinal malignancies and rare disease populations. The project leverages the principal investigator's...
- Federal Project Grant Summary Colorado State University received a $629,341 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on September 12, 2025, with an ultimate completion date of August 31, 2030. The research project focuses on developing improved cancer treatment methods through investigation of Focal Adhesion Kinase (FAK) inhibition as a dual-targeting strategy for osteosarcoma, the most common primary malignant...
- Federal Project Grant Award Summary The University of Colorado-Denver received a $547,080 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective September 17, 2025 through August 31, 2029. This award supports the University of Colorado Cancer Center's (UCCC) initiative to advance cancer screening and prevention clinical trials. Under the direction of Dr. Wood, the Deputy Director of the Cancer Control Program, the funded...
- Federal Grant Award Summary The National Cancer Institute awarded $138,846 to the University Health Network under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for a two-year Project Grant commencing August 1, 2025 and concluding July 31, 2027. The award supports the development of laboratory-generated "wild-like" mouse models designed to enhance the translational relevance of preclinical cancer and immunotherapy research. The primary deliverable involves adapting...